BUTAZOLIDIN Drug Patent Profile
Which patents cover Butazolidin, and when can generic versions of Butazolidin launch?
Butazolidin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in BUTAZOLIDIN is phenylbutazone. There is one drug master file entry for this compound. Additional details are available on the phenylbutazone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BUTAZOLIDIN?
- What are the global sales for BUTAZOLIDIN?
- What is Average Wholesale Price for BUTAZOLIDIN?
Summary for BUTAZOLIDIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| DailyMed Link: | BUTAZOLIDIN at DailyMed |
US Patents and Regulatory Information for BUTAZOLIDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | BUTAZOLIDIN | phenylbutazone | CAPSULE;ORAL | 008319-009 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | BUTAZOLIDIN | phenylbutazone | TABLET;ORAL | 008319-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
